Core Insights - NanoViricides, Inc. announced that its clinical lead drug NV-387 has demonstrated strong efficacy against the Measles virus in a humanized animal model [1] - The company is preparing to make NV-387 available for emergency use application in response to ongoing Measles outbreaks [1] Company Summary - NanoViricides, Inc. is a publicly traded company listed on NYSE American under the ticker NNVC [1] - The company focuses on developing antiviral therapies, with NV-387 being a significant advancement in its pipeline [1] Industry Context - The announcement comes amid a rising number of Measles outbreaks, highlighting the urgent need for effective treatments [1] - The potential emergency use of NV-387 could position the company as a key player in addressing public health challenges related to viral infections [1]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive has a presence in key finance and investing hubs with bureaus and studios located in London, New York, Toronto, Vancouver, Sydney, and Perth [2][3] Group 2 - The company is committed to using technology to enhance workflows and has adopted various technological tools [4] - Proactive employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]